Scientari is building an ecosystem of strategy guides, interactive analysis tools, and decision systems for biotech and pharma professionals.
Clinical Trial Protocol Optimization
Most Phase 2 failures aren’t drug failures — they’re design failures. TrialReadiness scores a protocol’s measurement architecture on a 0–40 scale before the first patient is enrolled, surfacing where timing and assessment density could bury a real signal. Grounded in a retrospective analysis of 275,000 trials. Most recommendations re-allocate samples you’re already collecting rather than adding patient visits.
Drug Repositioning Intelligence
Repositioning drives roughly 30% of FDA approvals, but a single BD&L evaluation still burns 200+ analyst hours and up to $75K in consultant fees — often without a clear answer. Scientari’s Repothesis™ platform scores every compound–indication pair on scientific evidence and commercial viability independently, delivering a board-ready repositioning call at a fraction of the time and cost.
AI-Native Biotech Tracker
Every biotech now says it uses AI. Far fewer can show that AI actually produced their drugs. Scientari’s AI-Native Biotech Tracker separates the two. A company qualifies as AI-native only when learned models sit on the critical path to discovery, meaning they originated the molecule or identified the target. Companies whose AI is post-hoc tooling, infrastructure, or marketing do not qualify. The tracker covers the companies, their pipelines, the partnerships and deals behind them, and the clinical AI that supports them. Every entry is sourced, and every correction is logged publicly.
In Development
Scientari is developing additional tools for startup funding, sequencing needs analysis, and strategic guides (regulatory, drug delivery technology, orphan designation).